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1. INTRODUCTION
jj Staphyloccocus aureus (S. aureus) is a major pathogen in CF, usually the first to be found 
in young children. 
jj S. aureus can be divided in
js meticillin-sensitive Staphyloccocus aureus (MSSA) and
js meticillin-resistant Staphyloccocus aureus (MRSA)
jj The prevalence of MSSA and MRSA infection in CF patients in Europe is 17-54% and 3.5-
13%, respectively.
jj In chronic infection with S. aureus, sputum culture on agar plates may show small colony 
variants (SCV) that are associated with an increased rate of antimicrobial resistance and 
lung deterioration.
jj Cases of severe pulmonary infection due to strains expressing Panton-Valentine Leukocidin 
(PVL, a cytotoxin associated with aggressive pyogenic infections) have been described in 
CF patients. Research of PVL in respiratory samples is conducted with specific PCR in 
reference centers such as university hospital laboratories. PVL research may be recom-
mended in case of severe infection due to MSSA or MRSA. 
2. METICILLIN-SENSITIVE STAPHYLOCCOCUS AUREUS (MSSA)
jj Adults carrying MSSA are usually chronically infected and therefore, eradication is not an 
issue. In children, long term prophylactic antibiotherapy to prevent S. aureus infection has 
led to higher rates of P. aeruginosa infection. 
jj There are no guidelines on the treatment of MSSA exacerbations in adult CF patients. 
Thus, the number of antibiotics (1 vs 2), the way of administration (oral, intravenous), and 
the duration of treatment are not predefined but should be guided by exacerbation and 
illness severity. 
jj The choice of antibiotics is based on in vitro sensitivity and treatment duration is usually  
14 days. In non-severe cases, one antibiotic given orally should be sufficient (Table 1). 
jj Important aspects concerning MSSA treatment are presented in Table 2.
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 Table 1 :  Antibiotics for MSSA in adult CF patients1,2
Antibiotic Dosage Comments
IV Cefazolin 1.5 g every 6h or 
2 g every 8h 
max. 6g/day
Cefuroxim 1.5 g every 8h
Co-amoxicillin 2.2 g every 8h
Flucloxacillin 2 g every 6h
Oral Co-amoxicillin 625 – 1000 mg every 8h
Cefuroxime 500 mg every 12h
TMP/SMX 160/800 mg every 8h may strongly select for S. aureus SCV1
Flucloxacilline 1-2 g every 6h
Cefaclor 750 mg every 12h max. 4g/day
Doxycycline 200 mg on 1st day and then 
100-200 mg every 24h
Minocyclin 100 mg every 12h
Clarithromycin 500 mg every 12h
Clindamycin 600 mg every 6h
IV: intravenously, TMP/SMX: trimethroprim/sulfamethoxazole, SCV: small colony variants
1In case of SCV, treatment should be individualized according to in vitro susceptibility
 Table 2: Important points concerning treatment of MSSA1,2 
Broad spectrum cephalosporins should be avoided
Ciprofloxacin should be avoided in the exception of concomitant infection with P. aeruginosa or 
intolerance/allergy to other classes of antibiotics
In patients chronically treated with azithromycin, macrolides should be avoided because of the 
high risk for macrolide resistance
In exacerbations of moderate severity, administration of a anti-staphylococcal penicillin or a 
narrow spectrum cephalosporin given intravenously should be considered
In case of necrotizing pneumonia due to PVL-producing MSSA, the addition of an antitoxin 
antibiotic (clindamycin, linezolid) is recommended
In cases of a severe exacerbation or an exacerbation in a severely-ill patient, clinicians should 
consider the presence of other pathogens, such as P. aeruginosa. In this situation, a combina-
tion of intravenous penicillin (e.g. tazobactam-piperacillin) or meropenem + oral ciprofloxacin 
or intravenous aminoglycoside (e.g. tobramycin, amikacin) should be considered.
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3. METICILLIN-RESISTANT STAPHYLOCCOCUS AUREUS (MRSA)
jj MRSA prevalence is increasing and this may be partially due to the use of broad spectrum 
antibiotics. 
jj MRSA acquisition is associated with a faster decline of FEV1 and reduced survival in CF. 
jj Chronic infection with MRSA decreases the recovery of pulmonary function following a 
respiratory exacerbation. 
jj Since MRSA is highly transmissible, CF patients infected with MRSA need to be isolated 
when they are in a healthcare environment.
jj As for MSSA, no clear recommendations for MRSA eradication or pulmonary exacerbation 
treatment are available. 
js A recent Cochrane review (Cochrane MRSA) could not establish recommendations 
on MRSA eradication in CF patients based on published studies but results of several 
non-randomized trials suggest that MRSA can be eradicated. 
js Although one-third of patients may clear MRSA spontaneously, considering the 
 increased morbidity associated with MRSA infection in CF, experts recommend to start 
an eradication regiment at the first positive culture.
js In a  recent  retrospective  study  from  the  Royal  Brompton  Hospital  (Hall H et al. 2015),   
dual regiments  were superior to a single antibiotic for MRSA eradication.  Particularly, 
the  association of  rifampicin 300 mg every 12h and  fusidic acid 500 mg  every 8h for 
14 days  given in newly and chronically infected patients, was associated  with an 
immediate  success rate of 82.6%. Cultures  were still  negative in 68% and  58.3% of  
patients at 6  months  and 12 months  respectively.
3.1 MRSA eradication regimens
jj Several protocols have been used in small non controlled trials. 
jj It is recommended to avoid long-term use of single agents such as TMP/SMX, rifampicin 
or fucidic acid. 
jj The most recent protocols are presented in Table 3. Drugs used for MRSA eradication 
and their dosages are presented in more detail in Table 4. 
js The choice of the protocol will depend on the clinical severity and patient drug tole-
rance. Different combinations of these drugs may be necessary.
js Discussion with the local microbiologist and infectious disease specialist is 
recommended.
3.2  Treatment of MRSA-associated pulmonary exacerbations
jj According to recent reviews, linezolid and vancomycin for 14 days are proposed as first 
choice drugs for MRSA-associated pulmonary exacerbations (Table 4 for dosages). 
However, because of potential serious side effects of both antibiotics (fewer with van-
comycin), other authors advocated that they should be reserved for severe MRSA infec-
tion requiring hospitalization.
jj In case of allergy/intolerance or in vitro resistance, consider tigecycline or teicoplanin or a 
combination of oral antibiotics based on sensitivity (e.g. rifampicin + fusidic acid).
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jj Ceftaroline (Zinforo®), a novel cephalosporin with activity against MRSA, may be an 
 appropriate option for treating MRSA lung infection, although CF-specific data are lacking.
 Table 3:  Examples of protocol for the eradication of MRSA (for dosage, see 
Table 4)1-5 
Protocol 11
(14 days)
TMP/SMX (320/1600 mg) + rifampicin 
+ standard topical treatment for nasal, throat and skin decontamination
Protocol 23
(14 days)
Rifampicin + fucidic acid
+ standard topical treatment for nasal, throat and skin decontamination
Protocol 35
(4 or 6 weeks)
1st line: doxycycline + TMP/SMX (160/800) or rifampicin or fucidic acid for 
6 weeks (according to in vitro sensitivity)
2nd line: if possible combination of rifampicin + fusidic acid for 6 weeks
3rd line: vancomycin or teicoplanin IV for 2 weeks 
followed by oral therapy combining doxycycline + TMP/SMX or rifampicin 
or fusidic acid for 4 weeks, or oral linezolid for 4 weeks
+ standard topical treatment for nasal, throat and skin decontamination
Protocol 44
(4 weeks)
Vancomycin nebulization (250 mg) every 12h
*Standard topical treatment consists of: 
nasal mupirocin (Bactroban® Nasal) for 14 days
+ topical chlorexidine body wash for 14 days
 Table 4: Antibiotics used for MRSA in aduls CF patients1-5
Antibiotic Dosage Comments
IV Vancomycin 1 g every 12h Risks: ototoxicity, 
nephrotoxicity, red man 
syndrome
Target serum concentration : 
15-20 mg/L
Linezolid 600 mg every 12h
Tigecycline 100 mg at first dose followed 
by 50 mg every 12h
Teicoplanin 400 mg at the first dose 
or 400 mg every 12 h (if severe 
infection) at the first day 
followed by 
200 mg or 400 mg (if severe 
infection) every 24h
TDM is recommended*1
(continued)
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Ceftaroline 600 mg every 12 h
Oral Rifampicin 300 mg every 12h Always in combination
TMP/SMX 160/800 mg every 8h or
320/1600 mg every 12h
May strongly select for S. 
aureus SCVs
Linezolid 600 mg every 12h
Fusidic acid 500 mg every 8h
Doxycycline 100 mg every 12h
Minocycline 100 mg every 12h
Levofloxacin Not recommended High risk of resistance
Inhaled Vancomycin*1,2 250 mg in 5 ml sterile H2O or 
0.9% NaCl every 12h
As bronchospasm may 
occur:
- administration of
bronchodilators before each
dose is recommended
- in case of severe
bronchial obstruction,
spirometry before and after
administration of the first
dose should be considered
Topical Mupirocin 2% Nasal : every 8h for 5 days
Chlorhexidine soap 
4%
or
Povidone-iodine 7.5%
Skin : every day for 5 days
Chlorhexidine 0.1% Throat : every 6-8h for 5 days
IV: intravenous, TMP/SMX : trimethroprim/sulfamethoxazole, SCVs : small colony variants, 
TDM: therapeutic drug monitoring 
*1 See also Chapter “Medications”
*2 At the time of writing not licensed for inhalation
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